Vaxart, Inc. (VXRT) — 10-Q Filings

10-Q Filings (6)

• Vaxart's Revenue Soars on Government Contracts, Dynavax Deal Boosts Cash — Nov 13, 2025 Risk: high
  Vaxart, Inc. (VXRT) reported a significant increase in revenue from government contracts for the nine months ended September 30, 2025, reaching $131.44 million,
• Vaxart's Revenue Soars on Government Contracts, Losses Narrow — Aug 13, 2025 Risk: high
  Vaxart, Inc. (VXRT) reported a significant increase in revenue from government contracts for the six months ended June 30, 2025, reaching $59.03 million, a subs
• Vaxart Q1 2025: $228M Assets, $0.4M Liabilities — May 13, 2025 Risk: low
  Vaxart, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported total assets of $228.2 million and total
• Vaxart Reports Q3 2024 Results, Net Loss of $153.5M — Nov 13, 2024 Risk: high
  Vaxart, Inc. filed its 10-Q for the period ending September 30, 2024, reporting total assets of $228.2 million and total liabilities of $0.7 million. The compan
• Vaxart Q2 2024: Assets $228M, Liabilities $154M — Aug 8, 2024 Risk: medium
  Vaxart, Inc. filed its 10-Q for the period ending June 30, 2024, reporting total assets of $228.1 million and total liabilities of $153.9 million. The company's
• Vaxart, Inc. Files 10-Q for Q1 2024 — May 13, 2024 Risk: high
  Vaxart, Inc. (VXRT) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Vaxart, Inc. reported $0 in revenue for Q1 2024, a decrease from $5,000,000 in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX